Related Experiment Video
Updated: Jul 16, 2026
07:17
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
BNIP3 expression in follicular lymphoma
J Sington1, A Giatromanolaki, L Campo
1Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Histopathology
|March 31, 2007
Summary
BNIP3 protein is highly expressed in most follicular lymphomas, unlike in reactive cases. This finding suggests BNIP3 may indicate more aggressive lymphoma behavior and aid in diagnosis.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Follicular lymphoma is a common non-Hodgkin lymphoma.
- Bcl-2 family proteins play critical roles in apoptosis and cell survival.
- BNIP3 is a Bcl-2 interacting protein with poorly understood functions in lymphoma.
Purpose of the Study:
- To investigate the expression of BNIP3 in follicular lymphoma (FL) compared to reactive lymphoid hyperplasia (RLH).
- To assess the relationship between BNIP3 expression and Bcl-2, p53, caspase-3, and Ki67.
- To determine if BNIP3 can serve as a diagnostic marker for FL.
Main Methods:
- Immunohistochemistry was performed on follicular lymphoma and reactive lymphoid hyperplasia samples.
- Monoclonal antibodies were used to detect BNIP3, Bcl-2, p53, caspase-3, and Ki67.
- Expression levels were quantified and compared between groups.
Main Results:
- BNIP3 showed strong expression in most follicular lymphomas but was weak or negative in reactive lymphoid hyperplasia.
- BNIP3 expression was inversely related to Bcl-2 expression.
- No correlation was found between BNIP3 and proliferation markers (Ki67), p53, or caspase-3.
Conclusions:
- BNIP3 is significantly upregulated in follicular lymphoma, particularly in Bcl-2 negative cases.
- BNIP3 may be a marker for more aggressive behavior in follicular lymphoma.
- BNIP3 could be a useful diagnostic marker to differentiate FL from RLH.
